Provided by Tiger Trade Technology Pte. Ltd.

Cardiff Oncology, Inc.

1.12
-0.0600-5.08%
Post-market: 1.130.0100+0.89%17:14 EDT
Volume:628.31K
Turnover:715.52K
Market Cap:86.99M
PE:-1.89
High:1.21
Open:1.21
Low:1.11
Close:1.18
52wk High:3.31
52wk Low:0.7566
Shares:77.67M
Float Shares:75.24M
Volume Ratio:1.46
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5914
EPS(LYR):-0.6863
ROE:-94.08%
ROA:-46.73%
PB:3.28
PE(LYR):-1.63

Loading ...

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

TIPRANKS
·
Aug 12

William Blair downgrades Cardiff Oncology (CRDF) to a Hold

TIPRANKS
·
Aug 12

Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate

Benzinga Earnings
·
Aug 12

Cardiff Oncology Q2 Operating Expenses Fall on Lower R&D Costs

Reuters
·
Aug 12

Cardiff Oncology Q2 Operating Expenses USD 9.719 Million

THOMSON REUTERS
·
Aug 12

Cardiff Oncology Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 12

Cardiff Oncology Gugat Nerviano Atas Sengketa Lisensi Onvansertib

Reuters
·
Aug 12

Cardiff Oncology Rugi Bersih FY26 Kuartal II Menyempit Menjadi USD 21,6 Juta; Revenue Tetap USD 0,1 Juta

Reuters
·
Aug 12

Cardiff Oncology Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Jul 25

Cardiff Oncology CEO Mani Mohindru Acquires 34,364 Shares Worth $50,002.62

Reuters
·
Jul 17

Cardiff Oncology Issues Warrants to Buy 9,303,136 Shares in Registered Direct Offering

Reuters
·
Jul 15

Cardiff Oncology Announces $10 Million Registered Direct Offering

THOMSON REUTERS
·
Jul 15

Cardiff Oncology CEO Mani Mohindru acquires 24,703 common shares for $29,890.63

Reuters
·
Jun 22

Cardiff Oncology shareholders approve 2021 equity plan share increase to 15,150,000 shares

Reuters
·
Jun 12

Cardiff Oncology Cut to Hold From Buy by Craig-Hallum

Dow Jones
·
Jun 04

Cardiff Oncology downgraded to Hold from Buy at Craig-Hallum

TIPRANKS
·
Jun 04

Cardiff Oncology announces results from CRDF-004 trial

TIPRANKS
·
Jun 02

BRIEF-Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting

Reuters
·
Jun 02

Cardiff Oncology says Phase 2 trial shows 72.2% response rate for onvansertib combo in first-line RAS-mutated mCRC

Reuters
·
Jun 02

Cardiff Oncology - Median Pfs Not Reached in Onvansertib Plus Folfiri/Bevacizumab Arms

THOMSON REUTERS
·
Jun 02